Corcept的relacorilant有望进军21亿美元卵巢癌市场。
Corcept’s relacorilant could reach $2.1B ovarian cancer market
生物技术与制药领域的最新动态
Corcept’s relacorilant could reach $2.1B ovarian cancer market
Rezubio Pharmaceuticals discloses new drug conjugates to treat fibrosis
Lunan New Time Biotechnical reports new camptothecin derivatives and their ADCs
Shanghai Qingrun Pharmaceutical Technology synthesizes new GTPase KRAS mutant inhibitors
Beyang Therapeutics discovers salts of VEGFR inhibitors
Sunshine Lake Pharma divulges new PKMYT1 inhibitors
Appointments and advancements for Jan. 21, 2026
Financings for Jan. 21, 2026
In the clinic for Jan. 21, 2026
Other news to note for Jan. 21, 2026
Regulatory actions for Jan. 21, 2026
Korean universities patent new PAK4 degradation inducers
Novacell Technology reports new FPR2 agonists
Nippon Zoki Pharmaceutical synthesizes new GABA-A receptor subunit positive allosteric modulators
Novartis discovers new CDK inhibitors
Med-tech gainers and losers for Jan. 12-16, 2026
Regulatory actions for Jan. 20, 2026
Six drugs to watch in China for 2026
December blockbusters push biopharma deal value to record high
Early data lift Immunofoco’s solid tumor CAR T program